Invited Talks
2020 SelectBio: EV-Based Diagnostics, Delivery, and Therapeutics, San Diego, CA. February 17-18. “Extracellular Vesicles as Reprogramming Reagents for induced Tissue Regeneration (iTR)” (Keynote)
2020 Longevity Therapeutics Summit, San Francisco, CA. January 28-30, “Induced Tissue Regeneration (iTR) using Natural and Engineered Extracellular Vesicles”
2020 Phacilitate: World Stem Cell Summit, Miami, FL. January 23. “Derivation and Uses of Highly Pure, Non-Immunogenic Lineage Specific Stem Cell Lines”
2019 World Pharma Congress: Extracellular Vesicles: Biomarkers, Drug Delivery and Therapeutics..Boston, MA. June 17-18. "Cellular Sources of Extracellular Vesicles for Induced Tissue Regeneration"
2019 SelectBio: Extracellular Vesicle Based Dx and Rx Summit, San Diego, CA. March 28-29. “Induced Tissue Regeneration (iTR) Using Extracellular Vesicles”
2019 FreeMind -14th Annual Non-Dilutive Funding Summit, January 9 SF, CA, “AgeX’s Non-Dilutive Funding Journey: How AgeX Obtained Initial Non-Dilutive Funding for Our Programs”
2018 Gordon Research Conference on Extracellular Vesicles. Newry, Main Aug 22. “A Highly Diverse and Scalable Progenitor Stem Cell Bank for Identifying and Producing Therapeutic Extracellular Vesicles”
2018 World Preclinical Congress: Extracellular Vesicles, June 20-21. “Harnessing the diversity of highly scalable cell lines derived from human pluripotent stem cells for EV discovery and production"
2017 Extracellular Vesicles: Cambridge, UK, Sept 26-28. “Overcoming Barriers to Therapeutic Exosome Production using Highly Scalable and Pure Embryonic Progenitor Cell Lines”
2016 American Society for Exosomes and Microvesicles, Asilomar Conference Center, Oct 20-24. “Exosomes from Highly Scalable and Clonally-Derived Embryonic Progenitor Cells for Induced Tissue Regeneration (iTR)”
2016 Gordon Research Conference on Extracellular Vesicles: Biologic Effects and Therapeutic Potential of Extracellular Vesicles: Newry, Main, Aug 21-26. “Exosomes from Highly Scalable and Clonally-Derived Embryonic Vascular Progenitor Cells for Therapeutic Angiogenesis”